Literature DB >> 11304575

TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.

J W Said1, K K Hoyer, S W French, L Rosenfelt, M Garcia-Lloret, P J Koh, T C Cheng, G G Sulur, G S Pinkus, W M Kuehl, D J Rawlings, R Wall, M A Teitell.   

Abstract

Activation of the TCL1 oncogene has been implicated in T cell leukemias/lymphomas and recently was associated with AIDS diffuse large B cell lymphomas (AIDS-DLBCL). Also, in nonmalignant lymphoid tissues, antibody staining has shown that mantle zone B cells expressed abundant Tcl1 protein, whereas germinal center (GC; centrocytes and centroblasts) B cells showed markedly reduced expression. Here, we analyze isolated B cell subsets from hyperplastic tonsil to determine a more precise pattern of Tcl1 expression with development. We also examine multiple B cell lines and B lymphoma patient samples to determine whether different tumor classes retain or alter the developmental pattern of expression. We show that TCL1 expression is not affected by Epstein-Barr virus (EBV) infection and is high in naïve B cells, reduced in GC B cells, and absent in memory B cells and plasma cells. Human herpesvirus-8 infected primary effusion lymphomas (PEL) and multiple myelomas are uniformly TCL1 negative, whereas all other transformed B cell lines tested express moderate to abundant TCL1. This observation supports the hypothesis that PEL, like myeloma, usually arise from post-GC stages of B cell development. Tcl1 protein is also detected in most naïve/GC-derived B lymphoma patient samples (23 of 27 [85%] positive), whereas most post-GC-derived B lymphomas lack expression (10 of 41 [24%] positive). These data indicate that the pattern of Tcl1 expression is distinct between naïve/GC and post-GC-derived B lymphomas (P < 0.001) and that the developmental pattern of expression is largely retained. However, post-GC-derived AIDS-DLBCL express TCL1 at a frequency equivalent to naïve/GC-derived B lymphomas in immune-competent individuals (7 of 9 [78%] positive), suggesting that TCL1 down-regulation is adversely affected by severe immune system dysfunction. These findings demonstrate that TCL1 expression in B cell lymphoma usually reflects the stage of B cell development from which they derive, except in AIDS-related lymphomas.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304575     DOI: 10.1038/labinvest.3780264

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  23 in total

Review 1.  Molecular basis of CLL.

Authors:  Yuri Pekarsky; Nicola Zanesi; Carlo M Croce
Journal:  Semin Cancer Biol       Date:  2010-09-21       Impact factor: 15.707

2.  TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas.

Authors:  Jinsheng Weng; Seema Rawal; Fuliang Chu; Hyun Jun Park; Rakesh Sharma; David A Delgado; Luis Fayad; Michelle Fanale; Jorge Romaguera; Amber Luong; Larry W Kwak; Sattva S Neelapu
Journal:  Blood       Date:  2012-05-29       Impact factor: 22.113

3.  Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation.

Authors:  Rhine R Shen; David O Ferguson; Mathilde Renard; Katrina K Hoyer; Unkyu Kim; Xingpei Hao; Frederick W Alt; Robert G Roeder; Herbert C Morse; Michael A Teitell
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

4.  TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation.

Authors:  Ali I Kuraishy; Samuel W French; Mara Sherman; Marco Herling; Dan Jones; Randolph Wall; Michael A Teitell
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-04       Impact factor: 11.205

5.  Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Authors:  Harvey E Johnston; Matthew J Carter; Kerry L Cox; Melanie Dunscombe; Antigoni Manousopoulou; Paul A Townsend; Spiros D Garbis; Mark S Cragg
Journal:  Mol Cell Proteomics       Date:  2017-01-04       Impact factor: 5.911

6.  The TCL1 function revisited focusing on metabolic requirements of stemness.

Authors:  Maria Teresa Fiorenza; Alessandro Rava
Journal:  Cell Cycle       Date:  2019-09-29       Impact factor: 4.534

7.  T cell leukemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines.

Authors:  Csaba Kiss; Jun Nishikawa; Kenzo Takada; Pankaj Trivedi; George Klein; Laszlo Szekely
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

8.  Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas.

Authors:  Matthew J Frank; David W Dawson; Steven J Bensinger; Jason S Hong; Wendy M Knosp; Lizhong Xu; Cynthia E Balatoni; Eric L Allen; Rhine R Shen; Dafna Bar-Sagi; Gail R Martin; Michael A Teitell
Journal:  Blood       Date:  2009-01-15       Impact factor: 22.113

9.  High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.

Authors:  Marco Herling; Kaushali A Patel; Nicole Weit; Nils Lilienthal; Michael Hallek; Michael J Keating; Dan Jones
Journal:  Blood       Date:  2009-09-21       Impact factor: 22.113

10.  Epigenetic silencing of Stk39 in B-cell lymphoma inhibits apoptosis from genotoxic stress.

Authors:  Cynthia E Balatoni; David W Dawson; Jane Suh; Mara H Sherman; Grant Sanders; Jason S Hong; Matthew J Frank; Cindy S Malone; Jonathan W Said; Michael A Teitell
Journal:  Am J Pathol       Date:  2009-08-28       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.